Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases

US7576091B2 · kind B2 · utility

Assignee

• Cyclacel Limited · GB

Inventors

• Campbell McInnes · Irmo, US
• Mark Thomas · Liverpool, GB
• Shudong Wang · Nottingham, GB
• Neil McIntyre · Forfar, GB
• Nicholas James Westwood · Dundee, GB
• Peter Fischer · Oslo, NO

Key dates

• Filing date: Jan 6, 2006
• Grant date: Aug 18, 2009
• Expiry date: Jan 6, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein:X is S, O, or NH; “a” is a single bond; or “a” is a double bond and one of R3 and R4, and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO2-alkyl, CO2R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8, or an alkyl group optionally substituted with one or more R8 groups; R3, R4, R5, and R6 are each independently selected from H, R8, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent ═O; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, halogen, CF3, NO2, COR10, CN, COOR10, CONR10R11, SO2R10 or SO2NR10R11; R9 is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms sel…